Xiao Fang Pharma 小方制药
28 significant filings since 29 May 2026: 3 on regulatory inquiry, 14 on equity incentive and 6 on share issue, and 3 other kinds. The latest, on 27 Aug 2026: 关于2026年中期利润分配方案的公告. 1 unverified report logged, the latest on 3 Sep 2026.
自 29 May 2026 起有 28 份重大公告：regulatory inquiry 3 份、equity incentive 14 份、share issue 6 份，另有 3 类。最新一份（27 Aug 2026）：关于2026年中期利润分配方案的公告。记录了 1 条未经核实的报道，最新一条见于 3 Sep 2026。
No broker reports from the last twelve months are held for this company. Brokers covered 1,186 of the 2,361 SSE listings (50%) over the same period. 近十二个月无本公司研报；同期券商覆盖了 2,361 只 SSE 证券中的 1,186 只（50%）。
No broker has changed its rating on this company in the reports held.
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。